Ticagrelor in the management of coronary artery disease.
Krithika LoganathPhilip D AdamsonAlastair James MossPublished in: Future cardiology (2020)
Ticagrelor is a potent and orally active P2Y12 inhibitor. Ticagrelor has been extensively tested in Phase II and Phase III trials in patients with coronary artery disease. The pharmacokinetics and pharmacodynamics of ticagrelor result in more rapid and effective inhibition of platelet activation compared with other P2Y12 inhibitors. This has resulted in a reduction in recurrent major cardiovascular events in initial randomized controls trials comparing ticagrelor with clopidogrel. More recently, clinical trials have investigated the use of ticagrelor in patients with stable coronary artery disease and a high residual risk of coronary thrombotic events. In patients with stable coronary artery disease, the potent antiplatelet effect of ticagrelor is counterbalanced by an increased risk of major bleeding. Further research is ongoing to determine the optimal duration of ticagrelor therapy.
Keyphrases
- percutaneous coronary intervention
- coronary artery disease
- acute coronary syndrome
- cardiovascular events
- st segment elevation myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- phase ii
- phase iii
- clinical trial
- coronary artery bypass grafting
- open label
- double blind
- atrial fibrillation
- placebo controlled
- type diabetes
- heart failure
- mass spectrometry
- stem cells
- anti inflammatory
- multidrug resistant
- aortic valve
- mesenchymal stem cells
- sensitive detection
- aortic stenosis
- study protocol